Antifolates induce inhibition of amido phosphoribosyltransferase in leukemia cells.
The pathway for de novo biosynthesis of purine nucleotides contains two one-carbon transfer reactions catalyzed by glycinamide ribotide (GAR) and 5-aminoimidazole-4-carboxamide ribotide (AICAR) transformylases in which N10-formyltetrahydrofolate is the one-carbon donor. We have found that the antifolates methotrexate (MTX) and piritrexim (PTX) completely block the de novo purine pathway in mouse L1210 leukemia cells growing in culture but with only minor accumulations of GAR and AICAR to less than 5% of the polyphosphate derivatives of N-formylglycinamide ribotide (FGAR) which accumulate when the pathway is blocked completely by azaserine. This azaserine-induced accumulation of FGAR polyphosphates is completely abolished by MTX, indicating that inhibition of the pathway is at or before GAR transformylase (reaction 3; Lyons, S. D., and Christopherson, R. I. (1991) Biochem. Int. 24, 187-197). Three h after the addition of MTX (0.1 microM), cellular 5-phosphoribosyl-1-pyrophosphate has accumulated 3.4-fold while 6-methyl-mercaptopurine riboside (25 microM) induces a 6.3-fold accumulation. These data suggest that amido phosphoribosyltransferase catalyzing reaction 1 of the pathway is the primary site of inhibition. In support of this conclusion, we have found that dihydrofolate-Glu5, which accumulates in MTX-treated cells, is a noncompetitive inhibitor of amido phosphoribosyltransferase with a dissociation constant of 3.41 +/- 0.08 microM for interaction with the enzyme-glutamine complex in vitro. Folate-Glu5, MTX-Glu5, PTX, dihydrotriazine benzenesulfonyl fluoride, and AICAR also inhibit amido phosphoribosyltransferase.
Sant
M E
ME
Department of Biochemistry, University of Sydney, New South Wales, Australia.
Lyons
S D
SD
Phillips
L
L
Christopherson
R I
RI
D000582:Amidophosphoribosyltransferase / Q000037:antagonists & inhibitors*; D000620:Aminoimidazole Carboxamide / Q000031:analogs & derivatives / Q000378:metabolism; D000818:Animals; D001377:Azaserine / Q000494:pharmacology; D005493:Folic Acid Antagonists / Q000494:pharmacology*; D007942:Leukemia, Experimental / Q000201:enzymology* / Q000378:metabolism; D008727:Methotrexate / Q000494:pharmacology*; D008778:Methylthioinosine / Q000494:pharmacology; D051379:Mice; D011687:Purines / Q000378:metabolism; D011743:Pyrimidines / Q000494:pharmacology*; D012265:Ribonucleotides / Q000378:metabolism; D014407:Tumor Cells, Cultured
D005493:Folic Acid Antagonists; D011687:Purines; D011743:Pyrimidines; D012265:Ribonucleotides; C014978:glycineamide ribonucleotide; D008778:Methylthioinosine; D000620:Aminoimidazole Carboxamide; D001377:Azaserine; D000582:Amidophosphoribosyltransferase; C031143:AICA ribonucleotide; C024530:piritrexim; D008727:Methotrexate